Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Cardinal Health Inc (CAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Cardinal Health Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.09 (market cap $9.43B), while Cardinal Health Inc trades at $237.19 (market cap $55.88B). The key difference: Cardinal Health Inc is far larger — about 5.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Cardinal Health Inc pays a 0.86% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | CAH | |
|---|---|---|
Market Cap | $9.43B | $55.88B |
Sector | Health | Health |
52-Week High | $356.25 | $240.26 |
52-Week Low | $241.71 | $146.04 |
Enterprise Value | $9.18B | $59.91B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Cardinal Health (CAH) trades at $236.87, down 0.13% on the day, near its 52-week high. The stock shows strong momentum with four consecutive quarterly EPS beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Technical indicators are bullish overall, with moving averages supporting upward trends. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%.
Outlook remains positive driven by robust pharmaceutical demand and optimistic FY2027 guidance. Key risks include high debt levels and thin profit margins. Analysts maintain a bullish consensus with a $266.43 price target, representing 12.5% upside. The stock presents a growth opportunity but requires monitoring of margin pressures and cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
